Skip to main content
. 2023 Jul 6;75:101773. doi: 10.1016/j.molmet.2023.101773

Figure 4.

Figure 4

HILPDA reduces ATGL protein levels in adipocytes. A) HILPDA protein level in Hilpdaflox/floxand HilpdaΔADIPO SVF-derived adipocytes, B) HILPDA protein level in Hilpdaflox/flox and HilpdaΔADIPO SVF-derived adipocytes treated with 10 μM isoproterenol for 3 h. C) Free glycerol and D) NEFA concentration in the culture medium of Hilpdaflox/flox and HilpdaΔADIPO SVF-derived adipocytes treated with 10 μM isoproterenol for 3 h. N = 3. E) HILPDA and ATGL protein levels in Hilpdaflox/flox and HilpdaΔADIPO SVF-derived adipocytes treated with E) 600 μM OA: PA for 12 h, F) DGAT1/DGAT2 inhibitors for 2 h, G) 10 μM isoproterenol for 3 h, H) 10 μM MG132 for 14 h, or I) 20 μM TUG-891 for 24 h. L. e., long exposure; s. e., short exposure. Western blots were probed with antibodies against HILPDA, ATGL, and HSP90. Asterisk indicates significantly different according to Student's t-test. ∗∗P < 0.01.